p62在结直肠癌中的表达及其临床应用的研究进展  

Research Progress on the Expression of p62 in Colorectal Cancer and Its Clinical Application

作　　者：奉莅 付敬伟[2] 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁市第一人民医院胃肠外科,山东 济宁

出　　处：《临床医学进展》2024年第4期1241-1247,共7页Advances in Clinical Medicine

摘　　要：结直肠癌(CRC)作为一种常见的恶性肿瘤,其发生和发展涉及多个复杂因素。在CRC的病理生理过程中,p62作为一种细胞自噬相关蛋白,参与了肿瘤细胞的增殖、凋亡、侵袭和转移等关键生物学事件。本综述从p62的功能及调控机制、p62在结直肠癌的发生发展相关性研究、p62作为治疗靶点的应用前景系统综合并总结了p62在结直肠癌中的表达及其临床应用的最新研究进展,以期在未来的结直肠癌的诊治提供可靠的依据。Colorectal cancer (CRC), as a common malignant tumor, involves multiple complex factors in its occurrence and development. In the pathological and physiological processes of CRC, p62, as a cell autophagy-related protein, participates in key biological events such as tumor cell proliferation, apoptosis, invasion, and metastasis. This review comprehensively summarizes the latest research progress on the expression of p62 in colorectal cancer and its clinical applications, focusing on the functional and regulatory mechanisms of p62, its relevance to the development of colorectal cancer, and its potential as a therapeutic target. The aim is to provide a reliable basis for the diagnosis and treatment of colorectal cancer in the future.

关 键 词：结直肠癌 P62 表达 临床应用 

分 类 号：R73[医药卫生—肿瘤]